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Context.— Plasma human immunodeficiency virus type 1 (HIV-1) viral load and
CD4+ cell count are used to predict prognosis of persons infected with HIV. How-
ever, whether combining these markers improves prognostic accuracy and whether
theypredict prognosis for injectiondrugusers (IDUs)andnonwhitepersons infected
with HIV has not been extensively investigated.
Objective.— To evaluate plasma viral load and CD4+ cell count as prognostic in-
dicators for the acquired immunodeficiency syndrome (AIDS) and infectious
disease deaths.
Design.— Cohort study initiated in 1988 and 1989 with follow-up for up to 7.9
years.
Participants.— Injection drug users infected with HIV recruited from the com-
munity in Baltimore, Md.
Main Outcome Measures.— Plasma HIV-1 RNA and CD4+ cell count measured
at baseline compared with time to first clinical AIDS diagnosis and death due to an
infectious disease.
Results.— Of 522 subjects, 96% were African American, 80% were male, 96%
injected drugs within the past 6 months, and the median age was 33 years. A total
of 146 cases of AIDS and 119 infectious disease deaths were seen during a me-
dian follow-up period of 6.4 years. Time-fixed baseline levels of viral load and CD4+
cell count were independent predictors of progression to AIDS and infectious dis-
ease deaths, but in proportional hazards models, viral load had better predictive
value than CD4+ cell count. Kaplan-Meier analysis of time to AIDS and to infectious
disease deaths by viral load (,500, 500-9999, 10 000-29 999, $30 000 copies/mL)
at 3 levels of CD4+ cell count (,0.20, 0.20-0.49, and $0.503109/L [,200, 200-499,
and $500/µL]) was reduced to a 5-stage classification scheme using a backward
stepwise regression procedure. The 5-year cumulative probabilities for AIDS and
infectious disease deaths ranged from 0% and 0%, respectively, for group I (viral
load, ,500 copies/mL; CD4+ cell count, 0.503109/L) to 81.2% and 76.1% respec-
tively, for group V (viral load, $10 000 copies/mL; CD4+ cell count, 0.203109/L).
Conclusions.— In this study, plasma HIV-1 viral load independently and in
combination with CD4+ cell count measurements provided powerful prognostic in-
formation for progression to AIDS and death caused by infectious disease in a
population of predominantly African American IDUs. Combining categories of both
markers provided a simple method for prognostically staging HIV disease.
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CROSS-SECTIONAL STUDIES have
shown that higher titers of human immu-
nodeficiency virus type 1 (HIV-1) in pe-
ripheral blood mononuclear cells and
plasma are associated with lower CD4+
cell counts.1-5 Prospective studies of viral
burden in persons measured soon after
HIV infection (ie, seroconversion) found
higher viral load to be predictive of more
rapid progression of HIV-1 disease.6-9
More relevant to the typical clinical set-
ting, where date of onset of HIV-1 infec-
tion may be unknown to the physician,
higher plasma viral load also predicts
more rapid development of the acquired
immunodeficiencysyndrome(AIDS)and
death in seroprevalent persons.10,11 Viral
load reductions in response to antiretro-
viral therapies are predictive of subse-
quent clinical response.12,13
However, important questions remain
unansweredregardingtherelationshipbe-
tween CD4+ cell count and plasma HIV-1
viral loadandtheusefulnessofthesemark-
ers in combination as prognostic indica-
tors for AIDS and death. First, most stud-
ies have reported data largely from white
homosexual men and hemophilia pa-
tients.10,11,14 Whether interpretation of vi-
ral load from these studies can be ex-
tended directly to injection drug users
(IDUs), women, and minorities needs to
be clarified. Second, prior reports of prog-
nosismostlyconcentratedonshowingthat
viral load measurements are useful inde-
pendently of CD4+ cell counts.10 At-
tempts to combine these 2 measures to
establish more powerful and useful prog-
nostic classifications of HIV disease are
sparse.11 Moreover, from a clinical stand-
point, in the past decade and prior to avail-
ability of HIV-1 plasma viral load mea-
surements, prognostic and therapeutic
studies used CD4+ cell count cutoff values
of0.20and0.503109/L(200and500/µL).15,16
The ability of plasma HIV-1 RNA levels
JAMA, January 7, 1998—Vol 279, No. 1 Plasma Viral Load and CD4+ Cell Count—Vlahov et al 35
©1998 American Medical Association. All rights reserved.
tocontributeinformationwithinthesepre-
viously established CD4+ cell count cutoff
values requires clarification.
To address these questions, we evalu-
ated the prognostic value of plasma
HIV-1 RNA measurements in relation
to CD4+ cell count in a prospective study
of 522 HIV-1–seropositive IDUs en-
rolled in a cohort study in 1988 and 1989.
This cohort consists largely of African




The methods used for organization, re-
cruitment, and data collection have been
described.17 In brief, between February
1988 and March 1989, IDUs were en-
rolled in a longitudinal study of HIV-1 in-
fection. Subjects were recruited by word
of mouth from community sources, which
included drug abuse treatment centers,
city health department sexually trans-
mitted disease clinics, emergency de-
partments, state probation and parole of-
fices, university hospital HIV/AIDS
clinics, homeless shelters, and a street
AIDS prevention outreach program.
Study participants were also encour-
aged to refer eligible friends. Eligibility
criteria included age of at least 18 years,
injection drug use within the previous 11
years, and absence of AIDS-defining ill-
ness. Study and consent procedures were
reviewed and approved by the Institu-
tional Review Board of the Johns Hop-
kins School of Hygiene and Public Health.
Of 2960 IDUs recruited, 704 were
HIV seropositive at baseline. All HIV-
1–seropositive persons were invited to
enroll in the cohort for detailed clinical
and laboratory follow-up. Consenting
subjects (664 HIV-1–seropositive per-
sons) agreed to return at 6-month in-
tervals for interviews, physical exami-
nations, and venipuncture and signed
release forms for us to obtain medical
records to confirm the diagnosis of
AIDS. Annual rates of continued par-
ticipation in the follow-up clinic consis-
tently exceeded 91%.
Data Collection
A baseline interview obtained informa-
tion on age, race, sex, injection drug use
within 6 months prior to enrollment (“cur-
rent” drug use), and presence or absence
of several symptoms during the 6 months
prior to interview. Those symptoms in-
cluded fatigue, unintentional weight loss
(.4.5kg),oral thrush,shortnessofbreath,
and diarrhea of 2 or more weeks’ dura-
tion. Given the near universal reports of
lymphadenopathy, fever,andnightsweats
in pilot studies, which we considered re-
lated to illicit drug use, these were ex-
cluded from the final instrument. For
analysis, at each follow-up visit we asked
subjects about intercurrent illnesses, di-
agnoses, and utilization of health care ser-
vices;positive responseswere followedby
a request for consent to obtain medical re-
cords.Medicalrecordswereabstractedus-
ing standard forms by trained nurses, and
final diagnoses were established by a phy-
sician-led end points committee. The out-
come variable, AIDS, was diagnosed ac-
cording to clinical criteria used in the 1993
Centers for Disease Control and Preven-
tion criteria18 based on review of medical
records through January 1997. Mortality
wasascertainedthroughaNationalDeath
Index search and through retrieval of
death certificates through January 1997.
Laboratory Studies
Antibodies to HIV-1 were detected by
commercial enzyme-linked immunosor-
bent assay (ELISA; Genetic Systems,
Seattle, Wash) with confirmation of re-
peatedly reactive ELISA tests by West-
ern blot (DuPont, Wilmington, Del).
For measurement of T-cell subsets,
heparinizedwholebloodwasstainedwith
monoclonal antibodies using a modified
whole blood method,19,20 and percentages
of CD3+, CD4+, and CD8+ T cells were de-
termined by flow cytometry. Using these
percentages along with automated com-
plete blood cell count and differential, we
determined absolute count of CD3+,
CD4+, and CD8+ T-cell subsets.
Quantitation of HIV-1 RNA was
performed using a second-generation
branched-chain DNA signal amplifica-
tion assay (Chiron Corp, Emeryville,
Calif) with a quantification limit of 500
copies/mL and a linear dynamic range
between5.03102 and1.53106 copies/mL.
Heparinizedplasmaspecimensforquan-
titation of viral load were processed
within 4 to 6 hours of collection and
stored at −70°C until testing. Assays
were performed in duplicate using 1-mL
aliquots; 97% of duplicate specimens had
a coefficient of variation below 30%,
which is the standard specified by the
manufacturer. Baseline levels of CD4+
cell count and plasma HIV-1 RNA were
used in this analysis.
Statistical Analyses
Analyses were performed using 2 pro-
gression end points: (1) first clinical AIDS
diagnosis, and (2) death due to an infec-
tious disease. While all-cause mortality in
people diagnosed as having AIDS is a
typical end point in studies involving
other populations, HIV-1 immunosup-
pressed IDUs are more likely than other
groups to develop non–AIDS-defining
bacterial infections or to die of trauma or
drug overdose.21,22 To increase the HIV-
AIDS specificity of mortality in this co-
hort, we used only deaths due to infec-
tious diseases (eg, an AIDS-defining di-
agnosis, nonrecurrent bacterial pneumo-
nia, bacterial sepsis, endocarditis, and
pyogenic meningitis) for mortality.
Kaplan-Meier estimates23 were ob-
tained separately on clinical AIDS and in-
fectious disease deaths by single base-
line levels of CD4+ cell count (stratified by
levels of 0.20, 0.20-0.49, and $0.503109/L
and by single baseline HIV-1 RNA lev-
els (,500, 500-9999, 10 000-29 999, and
$30 000 copies/mL). These strata of CD4+
cell count reflect the commonly used stag-
ing of HIV-1 disease by this measure. The
categorization of HIV-1 RNA levels re-
flects several characteristics, namely, (1)
a distinction between undetectable (,500
copies/mL) and low detectable levels, and
(2) within the range of detectable values
forthiscohort the medianandupperquar-
tile were rounded to 10 000 and 30 000 cop-
ies/mL, respectively. The censoring time
was the date of either the last semian-
nual study visit, AIDS, or death if these
occurred prior to January 1, 1996, or Janu-
ary 1, 1996, if these events occurred after
that date. We also constructed Cox pro-
portional hazards models separately for
AIDS and infectious disease deaths us-
ing baseline CD4+ cell count and baseline
HIV-1 RNA levels as continuous vari-
ables23; we used increments directly com-
parable to a prior report.10
We created a 334 cross-classification
table (to reflect the 3 CD4+ cell count and
the 4 HIV-1 RNA levels) and separately
fit Kaplan-Meier models of time to AIDS
and infectious disease deaths in 11 of the
strata. (No person fell into the strata
with HIV-1 RNA level of ,500 copies/
mL and CD4+ cell count of ,0.203109/L.
Five-yearprobabilities forAIDSandfor
infectious disease deaths for each stra-
tum are reported.
To achieve a simplified staging model
basedonthecombinedinformationofCD4+
cell count and HIV-1 RNA levels, cells
within the matrix were merged into clus-
terswithstatisticallysimilarsurvival func-
tions. This was done using a systematic
stepwise backward regression approach
that collapsed cells with similar survival
functions based on comparing log-
likelihoods of 2 regression models via the
likelihood ratio test.23 An initial model of
time to AIDS was created using separate
survival curves for each of the 11 strata.
At each step of the procedure, the num-
ber of cells was reduced by 1 by combin-
ing the adjacent pair of cells which re-
sulted in minimal change in log-likelihood.
This continued until reduction in number
ofcellsresultedinsignificantchangeinlog-
likelihoodatP=.05,meaningtherewasevi-
dence to reject the model with fewer cells
in favor of the model with more cells. This
procedure reduced the original 11 cells to
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5 cells in the final model. To assess ad-
equacy of the 5-stage model in this popu-
lation, CD4+ cell count and HIV-1 RNA
level were added as continuous variables
to the proportional hazards model of time
to AIDS that contained the HIV staging
variable (ie, the 5 groupings that com-
bined categories of CD4+ cell count and
HIV-1 RNA levels); interpretation was
guided by overall goodness-of-fit tests.
With the 5-level HIV staging variable
based on a combination of CD4+ cell
count and HIV-1 RNA level, we inves-
tigated the contribution of other vari-
ables such as demographic characteris-
tics and clinical symptoms in propor-
tional hazard models of time to AIDS.
Statistical significance was determined
by the Wald and likelihood ratio tests.23
The proportionality assumption of final
regression models was assessed using in-
teraction terms between coefficients and
log of time and found to be negligible in all
infectious disease death models (Tables 1
and 3) and with respect to baseline viral
load levels in the AIDS model (Table 1).
Although the effect of bDNA was consis-
tent with proportionality in the AIDS
model(Table1),theeffectofCD4+ wasnot
(P=.005). In a model that included an in-
teraction term for nonproportionality of
CD4+ overtime,weobservedrelativehaz-
ards at 2 and at 7 years of 1.40 and 1.07 per
100 CD4+ cells. In the staging model
(Table 3), there was a significant interac-
tion with time only for category V (com-
pared with II, the reference), where the
relativehazardsat2and7yearswere27.8
and 6.4, respectively. Despite these de-
partures from proportionality, direction-
ality of the results remains the same. Our
continuous model (Table 1) replicates a
prior model involving homosexual men.10
The finding that the effect of CD4+ cell
count diminishes over time, but viral load
does not, is consistent with the conclu-
sions of the prior report.10 We chose to
compare relative hazards at 2 and 7 years
as these years represent upper and lower
limits for occurrence of AIDS cases in our
study. Few AIDS cases (n=21) occurred
prior to 2 years of follow-up and 7 years
was the upper limit of the follow-up in this
study.
RESULTS
Of the 664 subjects enrolled in follow-
up, 11 had missing CD4+ cell counts at
baseline and 131 did not have sufficient
plasma in the repository to perform viral
load studies; these 142 were excluded
from further analyses. Comparison of de-
mographic and drug use characteristics
(ie, age, sex, race, injections within past 6
months, and percentage with clinical
symptoms)betweenpersonsincludedand
excluded from this analysis showed no
statistically significant differences.
In the 522 remaining HIV-1 seroposi-
tive participants, most were male (80%),
African American (96%), and currently
active drug injectors (96%). Median
baseline CD4+ cell count was 0.513109/L
(interquartile range, 0.35-0.713109/L).
The overall median HIV-1 RNA viral
load was 7630 copies/mL (interquartile
range, 1490-27 080 copies/mL). As 11%
had less than 500 copies/mL, the median
(and intraquartile range) for plasma vi-
ral load in the detectable range was
10 120 copies/mL (2660-30 770 copies/
mL),whichwasroundedto10 000copies/
mL (2500-30 000 copies/mL) for analy-
ses. Overall, 4.2% reported recent oral
thrush at baseline. Six percent were tak-
ing zidovudine (AZT) at baseline and
49.6% reported some use of mono-
therapy with nucleoside analogues dur-
ing the 7-year follow-up; use of protease
inhibitors and non-nucleoside reverse
transcriptase inhibitors were not re-
ported during follow-up.
The146casesofclinicalAIDSinthe522
seroprevalent subjects followed for a me-
dian of 6.4 years (range, 0.01-7.9 years)
translates to a crude annual incidence of
4.4%. Some had more than 1 presenting
condition at time of diagnosis and there
were a total of 160 presenting illnesses.
The 9 most frequently identified condi-
tions included Pneumocystis carinii
pneumonia(33),candidiasis (25esophage-
al, 1 pulmonary), Mycobacterium avium
infection (22), recurrent bacterial pneu-
monia (15), cryptocococcosis (15), AIDS
dementia (8), toxoplasmosis (3), esopha-
geal herpes (3), and “other” atypical my-
cobacterium infections (5); 18 cases of
AIDS-defining complications were iden-
tified at death, and the presenting illness
for these 18 was not further specified.
Overall, there were 182 deaths. Causes of
the 119 infectious disease deaths included
AIDS-defining complications (97), sepsis
(12), bacterial pneumonia (6), endocardi-
tis (3), and pyogenic meningitis (1). There
were 63 noninfectious causes of death, in-
cluding 26 due to drug overdose and 12
due to trauma; other noninfectious dis-
ease deaths included myocardial infarc-
tion, cerebrovascular accidents, cancer,
and end-stage organ failure.
In a time-fixed proportional hazards
model that used only baseline CD4+ cell
count and plasma viral load (Table 1), the
adjusted relative risks of AIDS and infec-
tious disease death within 7 years were
significant for both CD4+ cell count and
viral load. Viral load was more significant
in this respect than CD4+ cell count in
these models as indicated by the Wald x2
of 54.4 for viral load vs 25.1 for CD4+ cell
count in the proportional hazards model
for AIDS, and 63.3 and 10.6 for infectious
disease deaths, respectively. Neither
CD4+ cellcountnorHIV-1RNAlevelwas
associated with noninfectious disease
deaths in proportional hazards models.
Further analyses were restricted to the
3 categories of CD4+ cell count and the 4
categories of HIV-1 RNA levels as de-
fined (“Methods”). Figure 1 shows the cu-
mulative probability curves, derived from
the Kaplan-Meier procedures, for the on-
set of AIDS or infectious disease deaths
by the initial HIV-1 RNA level for the 3
categoriesofCD4+ cellcount.Forbothout-
comes, there was a significant trend to-
ward faster progression as the viral load
level increased within the CD4+ catego-
ries of 0.20-0.493109/L and less than
0.503109/L (P,.001 for all comparisons)
and within the less than 0.203109/L CD4+
cell count category (P=.02 for AIDS and
P=.003forinfectiousdiseasedeath),where
the sample size was small. Due to limited
samplesizewithinsubgroups, furtherpair-
wise comparisons were not performed.
However, descriptively, within the less
than 0.203109/L CD4+ cell count stratum,
there were no persons with viral load less
than 500 copies/mL; risk for AIDS and
death appeared similar between persons
in the 2 strata of the highest viral load cat-
egories and appeared higher than that of
persons with viral load of 500 to 9999 cop-
ies/mL (Figure 1A). In the 0.20 to
0.493109/LstratumofCD4+ cellcount,risk
of AIDS and infectious disease deaths ap-
peared higher in those with viral load
greater than 10 000 copies/mL than in
those with lower viral load levels (Figure
1B). For the greater than or equal to
0.503109/L CD4+ cell count stratum, the
risks for AIDS and infectious disease
deaths were similar for the middle catego-
ries of viral load and risks for the 2 out-
comes appear highest in those with viral
load levels of 30 000 copies/mL or more
(Figure 1C).
Data from the Kaplan-Meier curves
are summarized in Table 2 as 5-year cu-
Table 1.—Proportional Hazards Models for AIDS and Deaths Due to Infectious Disease by 3-Fold Increase
in Plasma HIV-1 RNA and 0.103109/L (100/µL) Decrease in CD4+ Cell Count*
Continuous
Variables









Plasma viral load 1.33 (1.24-1.42) 1.32 (1.23-1.42) 1.40 (1.29-1.51) 1.40 (1.29-1.52)
CD4+ cell count 1.23 (1.14-1.33) 1.20 (1.12-1.29) 1.14 (1.06-1.23) 1.12 (1.05-1.21)
*AIDS indicates acquired immunodeficiency syndrome; HIV-1, human immunodeficiency virus type 1; RH, relative
hazard; and CI, confidence interval.
†Adjusted relative hazards are for models that included both plasma viral load and CD4+ cell count.
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mulative probabilities for AIDS and
death due to infectious disease and show
a consistent pattern of increasing risk
for AIDS and death across increasing
levels of plasma viral load and across de-
creasing levels of CD4+ cell count.
To develop a more parsimonious HIV
prognostic staging system, we used the
data to construct groups based on simi-
larity of cumulative probability rates for
AIDS and infectious disease deaths using
the stepwise regression approach de-
scribed(“Methods”).Thisapproachyielded
5 prognostic staging groups that are de-
picted in Table 3 using the staging group
numbers I to V, with group I correspond-
ing to the lowest cumulative probabili-
ties. Following this procedure, as seen in
Table 2, we note that in group II, the risk
of AIDS and infectious disease death in
those with a moderate CD4+ cell count (ie,
0.20-0.503109/L) and undetectable (,500
copies/mL)to low(500-9999copies/mL)vi-
ral load is similar to that of those with high
CD4+ cell count (.0.503109/L) and low
(500-9999 copies/mL) to moderate (10 000-
29 999 copies/mL) viral load. Likewise, in
group III the risks for AIDS and infec-
tiousdiseasedeathweresimilarandthere-
fore grouped for those with low CD4+ cell
count and low viral load, moderate CD4+
cellcountandmoderateviral load,andhigh
CD4+ cell count and high viral load.
As illustrated by the separate Kaplan-
Meier curves of time to AIDS and infec-
tiousdiseasedeaths(Figure2)andthepro-
portional hazards model in Table 3, the 5-
group staging model provides strong
discrimination for both AIDS and infec-
tious disease death in this population.
There is not only a trend toward less
AIDS-free time (P,.001) and worse sur-
vival (P,.001) as we shift to a higher
group, but each group is also statistically
distinct from the comparison group II (ie,
Table 2.—Five-Year Cumulative Probabilities for AIDS and Deaths Due to Infectious Diseases by Strata of Plasma HIV-1 Viral Load and CD4+ Cell Count*
Viral Load
CD4+ Cell Count














Undetectable, ,500 copies/mL . . . . . . . . . 8.3 0.0 (15) II 0.0 0.0 (42) I
Low, 500-9999 copies/mL 57.7 14.3 (10) III 12.0 7.2 (96) II 9.1 5.4 (126) II
Moderate, 10 000-29 999 copies/mL 75.0 75.0 (5) V 35.2 15.6 (50) III 11.0 4.3 (57) II
High, $30 000 copies/mL 83.3 76.4 (16) V 42.4 32.3 (53) IV 23.0 14.6 (52) III
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Figure 1.—Kaplan-Meier curves of cumulative probabilities for the acquired immunodeficiency syndrome (AIDS) and for death due to infectious disease by 4 strata
of plasma human immunodeficiency virus type 1 (HIV-1) viral load for 3 strata of CD4+ cell count, the AIDS Link to Intravenous Experiences (ALIVE) study, Bal-
timore, Md, 1988-1996. There were significant linear trends by viral load in all strata of CD4+ cell count (P=.02 for AIDS within a CD4+ cell count ,0.203109/L
[,200/µL]; P=.003 for infectious disease death within a CD4+ cell count ,0.203109/L; and P=.0001 for all other categories). (In A and D, there were no HIV-infected
individuals with a CD4+ cell count of ,0.203109/L who had undetectable viral load [,500 copies/mL].)
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95% confidence interval [CI] excludes
unity). Addition of CD4+ cell count and vi-
ral load as continuous variables to the pro-
portional hazards model using the 5 stag-
ingcategorieswasnotsignificant(x2=5.99,
df=2,P..05).The5-yearcumulativeprob-
abilities for AIDS and infectious disease
death in the 5 categories are shown at the
top of Table 3 and ranged from 0% for
AIDS and infectious disease deaths in
group I to 81.2% for AIDS in group V.
Building on this classification scheme,
which was based on CD4+ cell count and
HIV viral load, we examined the poten-
tial contributions of demographic infor-
mation and presence or absence of clini-
cal symptoms at baseline. In bivariate
proportional hazard models performed
separately foreachofthevariables incom-
bination with the 5-stage CD4+ cell count
and viral load variable, oral thrush con-
tributedprognostic informationforthede-
velopment of AIDS (relative hazard, 2.45;
95%CI,1.30-4.62).Race,currentdruguse,
and number of clinical symptoms were not
statistically significantly associated with
AIDSorinfectiousdiseasedeathaftercon-




plasma HIV viral load independently and
in combination with CD4+ cell count pro-
vided a powerful predictor for progres-
sion to AIDS, and for death caused by in-
fectious disease, in our study population.
This study is unique because in contrast
to prior studies of this type, largely in-
volvingwhitehomosexualmen,thisstudy
includes mostly African American men
and women as well as large numbers of
active IDUs. Some earlier cross-sectional
dataonp24antigenemiahintedthatracial
or ethnic differences might be expected.24
Thus, an important finding is that the
samebasicrelationshipbetweenvirologic
and immunologic factors applies in Afri-
can American IDUs as in nonminority
persons from other risk groups. These re-
sultssupporttheconclusionthatthesame
level of aggressive therapy should be of-
fered irrespective of demographic or risk
group.
Other reports have tended to compare
the relative prognostic value for these 2
measuresofHIV-1diseasestageandhave
established that plasma viral load is a bet-
ter predictor for subsequent AIDS than
CD4+ cell count in homosexual men.9-11
Since clinicians now have at their dis-
posal 2 laboratory measures, each reflect-
ing different parameters of HIV infec-
tion, our objective was to examine the
combinedutilityofthese2measuresinpre-
dicting AIDS morbidity and mortality in
IDUs. Our data suggest that a single mea-
sure of a nondetectable plasma viral load
(ie,,500copies/mL)withaCD4+ cellcount
above 0.503109/L was associated with the
longest survival; conversely, persons with
anHIVRNAloadof30 000 ormorecopies/
mL and a CD4+ cell count of ,0.203109/L
had the highest probabilities of AIDS and
infectiousdiseasedeathinthenext5years.
At each level of CD4+ cell count, viral load
provided prognostic information about
probabilities of future AIDS and infec-
tious disease death. More important, data
presented here are confirmatory of re-




After accounting for both CD4+ cell
countandviral load,weexaminedwhether
demographic characteristics and clinical
symptoms provided additional prognos-
tic information. Inotherstudies,whichdid
notincludemeasurementofHIVviral load,
serum immune activation measures, such
as b2-microglobulin levels, have provided
prognostic information independent of
CD4+ cell count25,26; however, we did not
studythesemarkersbecausetheyhavenot
been adopted in clinical practice. Clinical
symptoms such as oral thrush have also
provided independent prognostic infor-
mationforthesubsequentdevelopmentof
AIDS26 as in our analysis. Age did not dif-
ferentiateprognosisashasbeenfoundelse-
where.24 Although about half of the co-
hort reported use of nucleoside analogue
monotherapy, because prescribed use is
more common in symptomatic patients27
and the effects are modest considering du-
ration of follow-up in this study,28 we did
not include their use as a factor in our
analysis. Effect of therapy in this study
probably results in more conservative es-
timates of association between baseline
measures and clinical outcomes.
Several caveats bear mentioning.
Plasma levels of HIV-1 RNA were mea-
Table 3.—Five-Year Cumulative Probabilities and Relative Hazards for AIDS and Deaths Due to Infectious Disease by HIV-1 Staging System
Staging Group†
I II III IV V
5-Year probabilities, %
AIDS 0 10.4 31.0 42.4 81.2
Infectious disease deaths 0 5.5 15.0 32.3 76.1
Relative hazards (95% CI)
AIDS 0.14 (0.02-0.98) 1.00 (Referent) 2.81 (1.89-4.16) 4.79 (3.03-7.59) 17.43 (9.83-30.94)
Infectious disease deaths 0.44 (0.11-1.82) 1.00 (Referent) 3.51 (2.24-5.52) 5.99 (3.58-10.03) 21.72 (11.83-39.86)
*AIDS indicates acquired immunodeficiency syndrome; HIV-1, human immunodeficiency virus type 1; and CI, confidence interval.
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Figure 2.—Kaplan-Meier curves of cumulative probabilities for the acquired immunodeficiency syndrome (AIDS) and for deaths due to infectious disease by 5 stages
(I-V) based on combination of plasma human immunodeficiency virus type 1 RNA and CD4+ T-lymphocyte measurements obtained at baseline visit, the AIDS Link
to Intravenous Experiences (ALIVE) study, Baltimore, Md, 1988-1996. There was a significant linear trend by disease stage for both AIDS (P,.001) and infectious
disease death (P,.001).
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sured using the bDNA assay on hepa-
rinized plasma specimens stored at
−70°C. While similar procedures were
followed in the MACS,9-11 which facili-
tates comparison of results between the
MACS and the AIDS Link to Intrave-
nous Experiences (ALIVE) studies,
higher levels of HIV-1 RNA degrada-
tion occur when using heparin rather
than ethylenediaminetetraacetic acid
(EDTA) as an anticoagulant and when
the processing time is longer than 4
hours between specimen collection and
storage.29 Studies that compared blood
specimens collected in EDTA vs heparin
over a range of processing times suggest
that plasma HIV-1 RNA levels reported
here are probably about half what they
would have been using the same assay if
specimens had been collected in EDTA
and processed within 4 hours.29 Other as-
says to measure plasma HIV-1 RNA are
available, including reverse transcrip-
tase polymerase chain reaction (RT-
PCR) and nucleic acid sequence based
amplification. Recently, studies that
comparedresultsofbDNAandRT-PCR
testing on the same MACS specimens
showed high correlation (r=0.93) be-
tween the 2 assays, but the RT-PCR re-
sults were about 2 times higher than
thosefromthebDNAassay.11 Thisneeds
to be considered when interpreting our
study results for clinical practice. While
newer assays may lower the limit of de-
tectable HIV-1 RNA below the 500 cop-
ies/mL of the assay used in this study,
the sensitivity of the bDNA assay used
here was adequate to provide important
prognostic information in this popula-
tion. However, more sensitive HIV-1
RNA assays might be useful to the cli-
nician to gauge the effect of antiretrovi-
ral therapy, since HIV-1 RNA levels be-
low the 500 copies/mL cutoff may be as-
sociated with an even better long-term
prognosis.
In conclusion, our analyses were fo-
cused on the combination of plasma
HIV-1 RNA levels and CD4+ T-lympho-
cyte counts as prognostic indicators for
AIDS and death in an IDU population
prior to the initiation of combination an-
tiretroviral therapies. Even at a time
when combination therapies are avail-
able, a prognostic indicator model devel-
oped using a cohort of IDUs, most of
whom were initially untreated and only
half of whomreceivedmonotherapy,may
be relevant. Large numbers of HIV-in-
fectedIDUsremainuntreatedbecauseof
a variety of factors, including limited ac-
cess to and utilization of health services.
In our population, despite aggressive re-
ferrals to HIV clinics, only 6% reported
use of antiretroviral combination thera-
pies in early 1997. Given appropriate en-
couragement, IDUs have shown interest
in their health and compliance with com-
plexregimens.30 Theprognostic indicator
model presented here provides clinicians
with a simple tool to help educate HIV-1
infected patients about viral load and
CD4+ cell count measurements and make
decisions regarding initiation of therapy.
This study was supported by grant DA04334 from
the National Institute on Drug Abuse and Coopera-
tive Agreement U54/CCU306802 from the Centers
for Disease Control.
The authors would like to thank the anonymous
reviewers for their contributions to this article.
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